adults became the bearers of the latest chronic disease to be associated with increased risk for cardiovascular disease
[MDPI] Mar M, Morales A, Colell A, Garca-Ruiz C, Fernndez-Checa JC
November 2025: One of the physicians and researchers who investigated the link between Wegovy and vision loss is continuing his research on a link between the drug and condition
The clinical data showed the 4 mg group achieving 17.1% body weight reduction at 48 weeks, which already exceeds what most single-receptor GLP-1 agonists deliver at their maximum doses
Sustainable success depends on integrating the medication with: A balanced, nutritious diet Regular physical activity, including strength training Behavioral support to build healthy habits The goal is to use the medication as a catalyst to achieve a healthier state that can be maintained for life
Sterility, precision, and consistency are essential for safety.